Co-treatment of municipal solid waste incineration fly ash and alumina-/silica-containing waste: A critical review.

Municipal solid waste incineration fly ash (MSWI-FA) is a hazardous by-product of the incineration process, characterized by elevated levels of heavy metals, chlorides, and dioxins. With a composition high in calcium but low in silicon/aluminum, MSWI-FA exhibits a poor immobilization effect, high energy demands, and limited pozzolanic activity when it is disposed of or reutilized alone. Conversely, alumina-/silica-containing waste (ASW) presents a chemical composition rich in SiO and/or AlO, offering an opportunity for synergistic treatment with MSWI-FA to facilitate its harmless disposal and resource recovery.

Is intraprocedural intravenous aspirin safe for patients who require emergent extracranial stenting during mechanical thrombectomy?

Background: Intraoperative antiplatelet therapy is recommended for emergent stenting during mechanical thrombectomy (MT). Most patients undergoing MT are also given thrombolysis. Antiplatelet agents are contraindicated within 24 hours of thrombolysis.

Intracellular Amyloid-β Detection from Human Brain Sections Using a Microfluidic Immunoassay in Tandem with MALDI-MS.

Alzheimer's disease (AD) currently affects more than 30 million people worldwide. The lack of understanding of AD's physiopathology limits the development of therapeutic and diagnostic tools. Soluble amyloid-β peptide (Aβ) oligomers that appear as intermediates along the Aβ aggregation into plaques are considered among the main AD neurotoxic species.

In-situ release and sequestration of CO in cement composites using LTA zeolites.

This paper investigates the impact of in-situ release and sequestration of CO on the compressive strength, volume of permeable voids, phase change, hydration reaction, and micro-morphology of cement mortars. Two Linde Type A (LTA) zeolites with micro-pore dimensions of 5 Å and 4 Å (i.e.

Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.

Background: This is a pilot proof-of-concept study to evaluate the utility of a custom 15-gene circulating tumor DNA (ctDNA) panel as a potential companion molecular next-generation sequencing (NGS) assay for identifying somatic single nucleotide variants and indels in non-small-cell lung cancer (NSCLC) patients. The custom panel covers the hotspot mutations in EGFR, KRAS, NRAS, BRAF, PIK3CA, ERBB2, MET, KIT, PDGFRA, ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 genes which serve as biomarkers for guiding treatment decisions in NSCLC patients.

Method: The custom 15-gene ctDNA NGS panel was designed using ArcherDX Assay Designer.